Relationship Between Oxytocin Level, Trust, and Attachment in Individuals With Borderline Personality Disorder
1 other identifier
observational
92
1 country
1
Brief Summary
We aim to assess the baseline oxytocin levels in individuals with borderline personality disorder and correlate those levels with social behavior, and compare the results with controls. Primary Hypothesis (H1): There is a significant difference in trust-related behavior as measured by oxytocin (OXT) levels between borderline personality disorder (BPD) patients and healthy controls. Secondary Hypotheses: H2: The trust-related behavior in BPD patients is significantly influenced by their level of emotional sensitivity. Specifically, higher emotional sensitivity in BPD patients is associated with lower trust-related behavior and vice-versa. H3: There is a significant correlation between trust-related behavior and childhood trauma in BPD patients. BPD patients with higher levels of reported childhood trauma will exhibit lower trust-related behavior compared to those with lower levels of trauma. H4: Trust-related behavior in BPD patients varies depending on their attachment styles. Specifically, BPD patients with insecure attachment styles will exhibit lower trust-related behavior compared to those with secure attachment styles. H5: There is a significant correlation between trust-related behavior and BPD severity. Patients with more severe BPD symptoms will exhibit lower trust-related behavior compared to those with less severe symptoms. H6: The levels of OXT in BPD patients will significantly correlate with their reported levels of emotional sensitivity, childhood trauma, attachment styles, and BPD severity. These hypotheses aim to address the complexities surrounding the modulation of trust-related behavior by oxytocin in BPD patients, taking into account various factors like emotional sensitivity, childhood adversity, attachment styles, and BPD severity. By testing these hypotheses, the study aims to provide a comprehensive understanding of the interplay between these factors in influencing trust-related behavior in BPD patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 7, 2023
CompletedFirst Posted
Study publicly available on registry
September 21, 2023
CompletedStudy Start
First participant enrolled
June 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2025
CompletedMay 24, 2024
May 1, 2024
1.2 years
September 7, 2023
May 22, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Correlation of Oxytocin levels and trust index
Day 1
Study Arms (2)
Cases
Participants with borderline personality disorder who meet the inclusion criteria
Controls
Participants without borderline personality disorder, who meet the inclusion criteria
Interventions
Both cases and controls will be assessed for their baseline serum oxytocin levels
To assess the level of emotional sensitivity in the participant
Eligibility Criteria
cases: individuals who are admitted to the inpatient psychiatry unit at a university hospital controls: healthy volunteers who volunteer to participate from the same city as the university hospital
You may qualify if:
- Individuals with borderline personality disorder will qualify as cases
- controls will be age, gender matched individuals without any psychiatric/mental health concerns
You may not qualify if:
- for all: pregnancy, hormonal or neurological disorders, and any kind of regular medication
- for controls: MacLEan screening instrument for BPD will be used at the time of screening to exclude BPD diagnosis in controls
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
SUNY Upstate Medical University
Syracuse, New York, 13210, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- M.D./PhD, Director of Inpatient Unit, Associate Professor, Department of Psychiatry and Behavioral Sciences
Study Record Dates
First Submitted
September 7, 2023
First Posted
September 21, 2023
Study Start
June 1, 2024
Primary Completion
August 1, 2025
Study Completion
September 1, 2025
Last Updated
May 24, 2024
Record last verified: 2024-05